219 related articles for article (PubMed ID: 33417490)
1. Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma.
Marqueen KE; Kim E; Ang C; Mazumdar M; Buckstein M; Ferket BS
JCO Oncol Pract; 2021 Feb; 17(2):e266-e277. PubMed ID: 33417490
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of selective internal radiation therapy with Y-90 resin microspheres for intermediate- and advanced-stage hepatocellular carcinoma in Brazil.
Agirrezabal I; Pereira Grillo Junior LS; Nasser F; Brennan VK; Bugano D; Galastri FL; da-Silva ALFA; Shergill S; da Motta-Leal-Filho JM
J Med Econ; 2023; 26(1):731-741. PubMed ID: 37139828
[TBL] [Abstract][Full Text] [Related]
3. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
[TBL] [Abstract][Full Text] [Related]
4. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma.
Zarca K; Mimouni M; Pereira H; Chatellier G; Vilgrain V; Durand-Zaleski I;
Clin Ther; 2021 Jul; 43(7):1201-1212. PubMed ID: 34059326
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
[TBL] [Abstract][Full Text] [Related]
7. NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with
Venerito M; Pech M; Canbay A; Donghia R; Guerra V; Chatellier G; Pereira H; Gandhi M; Malfertheiner P; Chow PKH; Vilgrain V; Ricke J; Leandro G
J Nucl Med; 2020 Dec; 61(12):1736-1742. PubMed ID: 32358087
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.
Hamdy Elsisi G; Nada Y; Rashad N; Carapinha J
J Med Econ; 2019 Feb; 22(2):163-168. PubMed ID: 30479174
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Ho JC; Hsieh ML; Chuang PH; Hsieh VC
Value Health Reg Issues; 2018 May; 15():120-126. PubMed ID: 29704658
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml.
Zheng H; Qin Z; Qiu X; Zhan M; Wen F; Xu T
J Med Econ; 2020 Apr; 23(4):347-352. PubMed ID: 31856618
[No Abstract] [Full Text] [Related]
13. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.
Chen S; Peng Z; Wei M; Liu W; Dai Z; Wang H; Mei J; Cheong M; Zhang H; Kuang M
BMC Cancer; 2018 Apr; 18(1):392. PubMed ID: 29621988
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma.
Liao W; Huang J; Hutton D; Zhu G; Wu Q; Wen F; Bai L; Li Q
Liver Int; 2019 Dec; 39(12):2408-2416. PubMed ID: 31544330
[TBL] [Abstract][Full Text] [Related]
15. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
[TBL] [Abstract][Full Text] [Related]
16. The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China.
Meng R; Cao Y; Zhou T; Hu H; Qiu Y
Front Public Health; 2022; 10():794131. PubMed ID: 35433574
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.
Shu Y; Tang Y; Ding Y; Zhang Q
Int Immunopharmacol; 2023 Sep; 122():110543. PubMed ID: 37406395
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
Leung HW; Liu CF; Chan AL
Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
[TBL] [Abstract][Full Text] [Related]
19. VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials.
Gebski V; Gibbs E; Gandhi M; Chatellier G; Dinut A; Pereira H; Chow PK; Vilgrain V
JMIR Res Protoc; 2017 Feb; 6(2):e17. PubMed ID: 28202430
[TBL] [Abstract][Full Text] [Related]
20. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]